← All news
Markets

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

1 source ·1 article ·Aug 31, 20:34 UTC Arrowhead Pharmaceuticals

Covered by 1 outlet

All coverage · 1 article